10-K/A: 180 Life Sciences Files Amendment to 10-K, Addressing Executive Compensation and Governance

180 Life Sciences Corp. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted disclosures regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Summary

• 180 Life Sciences Corp. filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
• The amendment addresses omissions in Part III, Items 10, 11, 12, 13, and 14 of the original filing, concerning directors, executive compensation, security ownership, related transactions, and principal accountant fees and services.
• The company does not expect to file its definitive proxy statement for the 2025 annual meeting within 120 days of December 31, 2024, necessitating this amendment.
• The amendment includes new certifications from the principal executive officer and principal financial officer.
• As of March 31, 2025, there were 5,185,780 shares of common stock issued and outstanding, including shares issuable upon conversion of Series B Convertible Preferred Stock.
• The aggregate market value of voting and non-voting common stock held by non-affiliates as of the last business day of the second fiscal quarter was $1,548,662.
• Blair Jordan serves as the Chief Executive Officer, with a salary of $240,000 per year.
• Eric R. Van Lent is the Chief Accounting Officer, compensated through EVL Consulting, LLC at $8,000 per month for an average of 10 hours of work per week.
• The Board of Directors has determined that Ryan Smith, Jay Goodman, and Stephen H. Shoemaker are independent directors.
• The company settled litigation with Tyche Capital LLC, resulting in a gain of $156,891 during the three months ended June 30, 2024.
• The company settled litigation with AmTrust, paying $250,000 and issuing 509,707 shares of common stock.
• The company is obligated to file a registration statement for the resale of the AmTrust Settlement Shares within 45 days of April 6, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily addresses compliance and legal matters, with both positive (settlements) and negative (legal disputes) aspects. There is no clear indication of significant positive or negative developments for the company's future prospects.

Positives

• The company has settled legal disputes with Tyche Capital LLC and AmTrust, resolving outstanding claims and potential liabilities.
• The company has appointed independent directors, ensuring oversight and governance.
• The company is taking steps to comply with SEC regulations by filing the necessary amendments to its annual report.
• The company has secured the services of experienced executives, including Blair Jordan as CEO and Eric R. Van Lent as Chief Accounting Officer.

Negatives

• The company had to amend its Annual Report on Form 10-K due to omissions in the original filing, indicating potential weaknesses in internal controls or reporting procedures.
• The company has been involved in multiple legal disputes, including actions against former executives and third parties, which can be costly and disruptive.
• The company has a history of executive turnover, with several changes in key positions such as CEO and CFO in recent years.
• The company has had to accrue and subsequently forgive salary reductions for certain executives, indicating financial constraints.

Risks

• Failure to maintain an effective registration statement for the resale of AmTrust Settlement Shares could result in significant liquidated damages.
• Ongoing legal proceedings and potential future litigation could have a material adverse effect on the company's financial condition and results of operations.
• The company's ability to attract and retain qualified personnel, including executive officers and directors, is critical to its success.
• The company's financial performance is subject to various risks and uncertainties, including the ability to raise capital and achieve its strategic objectives.

Future Outlook

The company is focused on complying with SEC regulations and resolving outstanding legal matters. The company is obligated to file a registration statement for the resale of AmTrust Settlement Shares by May 21, 2025.

Industry Context

This announcement reflects the company's efforts to maintain compliance with regulatory requirements and resolve legal disputes, which are common challenges for publicly traded companies, particularly those in the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• The executive compensation packages appear to be within the range of similar-sized companies in the biotech industry, but a detailed benchmarking analysis would be required for a more precise comparison.
• The legal settlements and associated costs are not uncommon in the biotech industry, where companies often face litigation related to intellectual property, regulatory compliance, and other matters.
• The company's corporate governance practices, including the appointment of independent directors and the establishment of audit and compensation committees, are consistent with industry standards and regulatory requirements.
• Comparable companies include other small-cap biotech firms listed on the Nasdaq Capital Market, such as Pasithea Therapeutics Corp. (KTTA) and BioAtla, Inc. (BCAB), where Lawrence Steinman also serves as a director.

Management Changes

Corporate Governance

Legal Proceedings

• The company settled litigation with Tyche Capital LLC and Ronald Bauer & Samantha Bauer.
• The company settled litigation with AmTrust International Underwriters DAC.
• The company is subject to ongoing legal proceedings, including the Declaratory Relief Action.

Related Party Transactions

• Service Agreement with Prof. Sir Marc Feldmann (former Co-Executive Chairman).
• Prof. Jagdeep Nanchahal Consulting Agreement.
• Prof. Lawrence Steinman Consultancy Agreement and Consulting Agreement.
• Jordan Consulting Agreement.
• EVL Consulting Agreement.
• Voting Agreements with Dr. James N. Woody and Dr. Marlene Krauss.
• Conversion of Series B Convertible Preferred Stock by Elray Resources, Inc.
• General and Administrative Expenses Related Parties.
• Accounts Payable Related Parties.
• Research and Development Expenses Related Parties.

Stakeholder Impact

• Shareholders: Resolution of legal disputes and improved corporate governance may enhance investor confidence.
• Employees: Executive compensation and potential changes in control could impact employee morale and job security.
• Customers: The company's focus on compliance and legal matters may indirectly affect its ability to deliver products and services.
• Suppliers: Settlement of legal disputes may improve the company's financial stability and ability to meet its obligations.
• Creditors: The company's financial condition and ability to raise capital are critical to its ability to repay debts.

Next Steps

• File a registration statement on Form S-1 (or Form S-3, if available) with the SEC within 45 days of April 6, 2025 (i.e., prior to May 21, 2025) to register the resale of the AmTrust Settlement Shares.
• Cause the Resale Registration Statement to be declared effective within 60 days following the Effective Date, or, in the event of SEC notice that the Registration Statement will not be reviewed, by the third business day thereafter.
• File a joint stipulation of dismissal with prejudice of the Coverage Action within ten days after delivery of both the Settlement Sum and the AmTrust Settlement Shares.

Key Dates

Keywords

executive compensation, corporate governance, directors, amendment, 10-K, litigation, settlement, related party transactions, independent directors, financial reporting